Status:
COMPLETED
Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Glioma
Eligibility:
All Genders
4-21 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents
Eligibility Criteria
Inclusion
- Age from 4th birthday and younger than 21st birthday
- Histologically documented malignant glial tumour (WHO classification grade III and IV) : astrocytoma, oligodendroglioma, oligoastrocytoma and mixed tumours
- Measurable and evaluable disease by the imaging criteria (MRI)
- Patient not previously treated by either of the two drugs
Exclusion
- Malignant brain stem tumours are excluded
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2007
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00147160
Start Date
October 1 2003
End Date
December 1 2007
Last Update
April 11 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave-Roussy
Villejuif, France, 94805
2
Bristol Royal Hospital for Children
Bristol, United Kingdom, BS2 8BJ